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Abstract
Mesenchymal stem cells (MSCs) are one of the most attractive therapeutic resources in clinical application owing to their
multipotent capability, which means that cells can differentiate into various mesenchymal tissues such as bone, cartilage,
fat, tendon, muscle and marrow stroma. Depending on the cellular source, MSCs exhibit different application potentials
according to their different in vivo functions, despite similar phenotypic and cytological characteristics. To understand the
different molecular conditions that govern the different application or differentiation potential of each MSC according to
cellular source, we generated a proteome reference map of MSCs obtained from bone marrow (BM), umbilical cord blood
(CB) and peripheral blood (PB). We identified approximately 30 differentially regulated (or expressed) proteins. Most up-
regulated proteins show a cytoskeletal and antioxidant or detoxification role according to their functional involvement.
Additionally, these proteins are involved in the increase of cell viability, engraftment and migration in pathological
conditions in vivo. In summary, we examined differentially expressed key regulatory factors of MSCs obtained from several
cellular sources, demonstrated their differentially expressed proteome profiles and discussed their functional role in specific
pathological conditions. With respect to the field of cell therapy, it may be particularly crucial to determine the most
suitable cell sources according to target disease.
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Introduction
Recently, pluripotent stem cells obtained from fetal tissue or
embryos have been a focus of research because of their ability to
give rise to a variety of differentiated cell types [1]. Accordingly,
many adult stem cell populations are also widely investigated for
clinical application in the regenerative medicine field [2,3].
Among them, mesenchymal stem cells (MSCs) have been
recognized as a representative stem cell population present in
adult tissue [4].
In 1976, Friedenstein et al. were the first to isolate MSCs from
bone marrow (BM-MSCs), a well-known stem cell reservoir, taking
advantage of their property of adhering to plastic dishes [5]. The
authors demonstrated that the MSCs grew as foci with a
fibroblast-like morphology, or colony-forming unit-fibroblasts
(CFU-F). In addition, the surface-marker expression profile was
verified to be positive for mesenchymal antigens (e.g., CD105,
CD13, CD31, and STRO-1) and matrix receptors (e.g., CD44,
CD29, and CD73) and negative for hematopoietic markers (e.g.,
CD34, CD45, and CD14) [6,7,8].
In addition to these phenotypic characteristics, MSCs also
retain the potential for self-renewal, a high proliferation rate in the
presence of defined growth factors and multipotent capacity,
which contributes to the regeneration of mesenchymal tissues such
as bone, cartilage, muscle, ligament, tendon, adipose and stroma
[9,10].
Owing to their multipotent capacity, BM-MSCs have been
investigated since their discovery as promising candidates for use
in new cell-based regenerative therapies [11]. However, it is
necessary to consider alternative cellular sources for isolating
MSCs because of the highly invasive method needed to obtain
bone marrow. Therefore, MSCs from different sources have been
actively studied; these sources include fatty tissue, placenta,
umbilical cord blood, peripheral blood, the pancreas, dental pulp
and synovial fluid [12,13,14,15].
MSCs obtained from different sources have been assumed to
exhibit similar phenotypic characteristics, irrespective of their
original source, as they all have self-renewal properties with
respect to common surface epitopes as well as multi-differentiation
potential. However, there is currently little information available
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differentiation or in vivo functions [16,17].
A detailed understanding of the molecular expression profile
governing different MSC applications according to their cellular
sources is essential for discovering the optimal cell type for clinical
use.
Gene expression analyses, such as microarray or DNA chip
array, should help in the discovery and elucidation of signaling
pathways and molecular mechanisms. However, the gene expres-
sion profile does not fully match the functional protein expression
profile [18].
In contrast to the transcriptome, proteome analysis can
elucidate important components of the proteome, such as protein
amount, stability, subcellular localization in a specific cell type or
organelle, post-translational modifications during specific devel-
opmental and physiological stages and interactions at the protein
level [19,20,21].
At present, two-dimensional gel electrophoresis (2-DE) and non-
2-DE-based approaches are broadly applied to proteomic
analyses. Proteome mapping serves as a starting point for building
a comprehensive database of the stem cell proteome. Proteomics
based on mass spectrometry (MS) has proven extremely useful for
analyzing complex protein expression patterns and, when applied
quantitatively, can be used to resolve subtle differences across
samples.
Several research groups have used proteomics to identify stem
cell-specific proteins in mouse ESCs (mESCs), human ESCs
(hESCs), human umbilical cord blood (UCB) MSCs, BM-MSCs,
rat NSCs and human NSCs [20,21,22,23].
Applying proteomics to investigate the programs that control
cell fate should provide valuable insight in understanding how the
factors determining their potentially differing applications and
which cell type is the most optimal cellular source in specific
pathological conditions.
In this study, we isolated MSCs from umbilical cord blood (CB-
MSC) and peripheral blood (PB-MSC), which are morphologically
and immune-phenotypically similar to MSCs obtained from the
BM (BM-MSC). We then compared the differentially expressed
protein profiles of BM-MSC, CB-MSC and PB-MSC to verify key
regulatory factors that govern potentially different applications
using 2-DE-based proteomic analysis tools. According to their
specific protein expression profile, we suggested a candidate for the
most optimal cellular source in specific pathological conditions in
the context of the regenerative medicine field.
On the basis of proteome analysis results, we suggested the
strong possibility that BM-MSCs and CB-MSCs have higher
viability with respect to ischemic disease than PB-MSCs owing to
their antioxidant and detoxification roles.
Also, we examined abundantly differentially expressed key
regulatory proteins such as carbonyl reductase 1 (CBR1), ornithine
aminotransferase (OAT), HSPB1 (HSP27), PDZ domain-contain-
ing protein GIPC1 (GIPC1) and PSAT1. Interestingly, the
expression of these proteins exhibited specific expression patterns
when they differentiated into adipocyte and osteoblast, regardless
of the expression pattern in the undifferentiated stage.
The discovery of the molecular expression associated with
specific functions and lineage differentiation capacities should
contribute valuably to the field of cell therapy by providing
information about the most suitable cell source to the target
disease. Therefore, our results provide useful information on the
selection of the optimal mesenchymal tissue as a primary source of
MSCs for certain purposes.
Results
Phenotypic characterization of MSCs obtained from cord
blood, peripheral blood and bone marrow
To confirm the phenotypic characteristics of cells obtained from
CB, PB and BM as MSCs, we performed morphological, RT-PCR
and FACs analysis. Three types of MSCs obtained from three
different cellular sources retained similar phenotypic characteris-
tics (Fig. 1).
Immediately after the isolation of CB-MSCs and PB-MSCs
using the Ficoll reagent, adherent colony-forming cells appeared
(see passage 0, Figure S1). After 14 days, proliferating MSCs
exhibited fibroblastic and spindle-like morphology after passage 3,
much like the purchased BM-MSCs (Fig. 1A).
Then, we compared the general marker expression profiles of
CB-MSCs, PB-MSCs and BM-MSCs at the RNA and protein
levels. In RT-PCR analysis, mesenchymal markers CD90 and
CD44 were expressed very strongly, whereas hemangioblast
marker CD133 and hematopoietic cell marker CD45 were not
detected (Fig. 1B).
In surface-marker expression analysis using the FACs analyzer,
CD34, CD45 (both hematopoietic cell markers) and CD133 were
expressed negatively in all paired samples, whereas they were
extremely positive for CD73 (adhesion marker, over 98%), CD44
(adhesion marker, over 97%), CD90 (mesenchymal marker, over
95%), CD105 (mesenchymal marker, over 99%), PDGF-B (over
77%) and HLA-ABC (over 97%) (Fig. 1C).
And cell growth rate is similar in all three cells (Fig. S2)
As the result, we confirmed that the isolated cells from CB and
PB in this study are also MSCs and are similar to purchased BM-
MSCs.
In vitro differentiation of MSCs derived from different
cellular sources
To investigate the differentiation capacity of MSCs derived
from different sources in vitro, MSCs were cultured in differenti-
ating induction medium for 4 weeks to induce adipogenic,
osteogenic and chondrogenic differentiation. Then, the differen-
tiation capacity of MSCs was characterized by immunocytochem-
istry and real-time RT-PCR.
The adipogenic differentiation potential of MSCs was deter-
mined by the lipid globule adipocyte colony formation and Oil
Red O positive staining when MSCs were cultured in adipogenic
differentiation media. The lipid globule adipocyte colonies
appeared after day 5, day 14 and day 22 in BM-MSCs, PB-
MSCs and CB-MSCs, respectively (data not shown). After 4
weeks, the adipocyte colonies were approximately the same size in
the BM-MSC- and PB-MSC-derived adipocytes, but CB-MSCs
produced fewer and smaller lipid vacuoles in contrast to those of
BM-MSCs and PB-MSCs. Additionally, the rate of Oil Red O-
positive colonies among cultured cell populations in differentiating
induction medium was varied. The rate of Oil Red O-positive
colonies was highest in BM-MSC and lower in PB-MSC. CB-
MSCs showed the lowest recorded rate of Oil Red O-positive
colony formation (Fig. 2A, upper panel).
When MSCs were cultured in an osteogenic medium, MSCs
displayed calcification colonies and a positive population under
Von Kossa staining of the mineralized matrix. To distinguish the
osteogenic differentiated cell population from each MSCs, we
performed Von Kassa immunostaining. Among the three different
MSCs, the rate of Von Kassa positive colonies was higher for BM-
MSCs than CB-MSCs and PB-MSCs (Fig. 2A, middle panel).
The chondrogenic differentiation of MSCs was induced via the
pellet culture method and confirmed by proteoglycan deposition
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chondrogenic differentiation media. Chondrogenic differentiated
pellets from BM-MSCs were clearly positive under Acian Blue
staining, whereas staining regions were very dim for CB-MSCs
and PB-MSCs.
To quantify the differentiation capacities of the three cell types,
real-time RT-PCR was performed to measure the expression of
genes specifically involved in adipocyte and osteoblast differenti-
ation. The relative expression levels of mRNA for PPARc2 and
ALP were used as markers of adipogenic and osteogenic
differentiation, respectively. The RNA expression of PPARc2
and ALP were significantly increased in adipogenic and osteogenic
differentiated cells from BM-MSCs, indicating that these cells
underwent adipogenic or osteogenic differentiation better than
other types of derived MSCs (Fig. 2. B).
These data indicated that BM-MSCs have a higher potential to
differentiate into adipocytes, osteocytes and chondrogenesis in vitro
than do other MSCs. As a result, despite the similar characteristics
of MSCs derived from different sources in the undifferentiating
state, MSCs retain variable differentiation potentials after inducing
differentiation.
Figure 1. Characterization of MSCs derived from BM, CB and PB. (A) Morphology of cultured BM-MSCs, CB-MSCs and PB-MSCs. MSCs showed
fibroblastic-like morphology. Magnification:640,6100. (B) RT-PCR analyses for genes expressed in MSCs. Oct4 and Nanog are undifferentiated stem
cell markers. CD90 is a positive marker of MSCs. CD133 is a negative marker of MSCs. (C) Flow cytometric analysis of cell surface markers of MSC from
BM, CB and PB. MSCs expressed CD90, and CD44 but not CD34, CD45, and CD133. CD34, CD45, and CD133 are negative markers, and CD90, and CD44
are positive markers.
doi:10.1371/journal.pone.0032350.g001
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To study the mechanism for elucidating the fundamental
differences among MSCs obtained from different cellular sources,
we harvested CB-MSCs, PB-MSCs and BM-MSCs at passage 2
and performed proteomic analysis using 2-DE analysis coupled
with mass spectrometry protein identification. Multiple gels from
the three independent replications were performed to certify the
reproducibility of the protein homogenates on 2-DE gels. The
analytical gels were visualized using silver staining.
As shown in Figure 3, (pH 3–10, molecular weight 18–200 kDa)
and despite similar general protein expression patterns in the three
types of MSCs, 11 of the proteins were abundantly up-regulated in
BM-MSCs and CB-MSCs, and 16 of the proteins were up-
regulated in PB-MSCs (Fig. 3. A, B and C). Consequently,
differentially expressed proteins were identified using LC-MS/MS.
Identified proteins were listed in Table S3, S4 and S5.
Classification of differentially regulated proteins based
on proteomic analysis
The list of identified proteins was then used to categorize their
functional involvement as documented in Gene Ontology (http://
www.geneontology.org) and UniProt (http://www.expasy.uniprot.
org) websites; the results were displayed as a graph (Fig. 3. D). A
Figure 2. Differentiation potential of MSCs isolated from BM, CB and PB (in vitro differentiation of MSC cultures). (A) Adipogenesis of
BM-MSCs, CB-MSCs, and PB-MSCs. Cells were stained with Oil Red O after 3 weeksin induction culture. The lipid globules of adipocytes were stained
red. Scale bar, 50 mm. Osteogenesis of BM-MSCs, CB-MSCs, and PB-MSCs. Cells were stained with Von Kossa after osteogenic induction for 3 weeks.
Calcium deposits of osteocytes were stained in brown. Scale bar, 50 mm. Chondrogenesis of BM-MSCs, CB-MSCs, and PB-MSCs. Cells were stained
with Alcian Blue after chondrogenic induction for 3 weeks. Proteoglycans deposits of chondrocytes were stained blue. Scale bar, 25 mm. (B) Relative
expression of adipogenic and osteogenic markers in BM-MSCs, CB-MSCs, and PB-MSCs before (d0, white bars) or after (d22, gray bars) induction of
differentiation. Data (n=3) are presented as the mean S.D., and asterisks indicate statistically significant values. The significance of differences was
evaluated by independent samples Student’s t-test (SAS version 8.0, Cary, NC, USA). *p,0.05, **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0032350.g002
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expressed proteins showed that these proteins have different roles
that can be broken down into five classification based on their
functions. This includes cytoskeleton proteins (i.e., tubulin alpha 1
C chain, annexin A2, Lamin B1, PDZ domain-containing protein
GIPC 1 and vimentin actin), antioxidant and detoxification
proteins (i.e., carbonyl reductase [NADPH], heat shock proteins
beta 1 (HSP 27), glutathione S-transferase Mu3, glutathione S-
transferase omega-1, S-formylglutathione hydrolase, anexxin A1,
and chloride intracellular channel protein 4), anti-apoptotic
proteins (i.e., isoform 1 of nucleophosmin and 40S ribosomal
protein S3), viral defense-related proteins (i.e., interferon-induced
GTP binding protein Mx 1 and ornithine aminotransferase), viral
defense-related enzymes (i.e., isoform 1 of phosphoserine amino-
transferase, L-lactate dehydrogenase, inositol monophosphatase
and nicotinamide N-methyltransferase) and development-related
protein (i.e., isoform 1 of axin interactor and dorsalization-
associated protein).
The largest category was the antioxidant and detoxification
group (26.92 %, or 2/26), whereas the second largest group was
the cytoskeletal category (23.08 %, or 2/26).
However, the distribution of the categories was very different
based on their cell source. Among BM-MSCs and CB-MSCs,
antioxidant and detoxification proteins were the largest category.
However, in the case of cytoskeletal proteins, PB-MSCs were the
most represented MSCs, although differences in the absolute
number of proteins were present.
Validation of functional relevance of proteome
expression profiled with therapeutic capacity of BM-, CB-
and PB-MSC
To investigate the functional relevance between protein
expression profile, which involved in antioxidant, detoxification
and cytoskeleton function, and each cell lines including BM-, CB-
and PB-MSC, we generated wound disease model and examined
the therapeutic capacity of each cell lines for 14 days.
Wound model is suitable disease model for comparison of
functional behavior of each cells in ischemic tissue, because wound
regions is rapidly fall into deep ischemic condition and wound is
one of the most frequently developed disease associated with
several kinds of ischemic disease model.
Figure 3. 2-DE gel electrophoresis and Classification of differentially regulated proteins from proteomic analysis. Proteins were
isolated from total protein of MSCs loaded onto the 2-DE gel electrophoresis. First dimension was 1 cm with a pH of 3 to 10 with NL IPG, and the
second dimension was 10% gels (A: BM-MSCs, B: CB-MSCs, C: PB-MSCs). They were visualized using silver staining. The number indicates the position
of up-regulated protein spots in the 2-DE pattern. (D) Ontological classification of differentially regulated proteins in terms of molecular functions
using the Gene Ontology (http://www.geneontology.org) and UniProt (http://www.expasy.uniprot.org) websites. The composition of the identified
proteins is presented as numbers for all individual identified proteins.
doi:10.1371/journal.pone.0032350.g003
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material and method section, we applied 3610
6 cells of each cells,
including BM-, CB- and PB-MSCs, to excisional wounds via
subcutaneous injection around the wound site. Vehicle control
medium were used as the negative controls. Wound healing was
then evaluated by photometric analysis of the wound tissue using
the calculating of wound closing rate as a relative value using an
image analysis tool (Image J) over 14 days.
Immediately after wounding with a biopsy punch (6 mm) device
on the both side of dorsal region, wounds displayed an epithelial
gap of 6.6760.27 mm, and the wound temporally became wider
because of wound contraction (data not shown). After three days,
wound closing could be detected as photometric analysis, and the
difference of wound closing rate between different cell lines,
including BM-, CB- and PB-MSCs, was more evidently after
8 days of cell transplantation (Fig. 4).
At 8 days, among three cell line treated group, including BM-,
CB- and PB-MSCs, CB-MSC-treated group exhibited a more
rapid healing rate than BM- and PB-MSC transplantation group.
In morphological and relatively calculated wound closing rate
analysis (P,0.05, n=6) using photometric result of wound region
8 days after cell transplantation (Fig. 4. A and B), remaining
wound size was reached at 58, 42 and 78 in BM-, CB- and PB-
MSC transplanted group, respectively (Fig. B, P,0.05, n=6),
when the remaining wound size was relatively calculated as 100 in
control vehicle group. These result indicate that the wound closing
was proceeded approximately about 42%, 58% and 22% in BM-,
CB- and PB-MSC transplanted group, respectively.
We then performed histological analyses on the central sections
of the wounds to evaluate the re-formation of granulation tissue on
wounded tissue and re-epithelialization at day 8 after cell
transplantation.
At day 8 after cell transplantation, the re-formation of
granulation tissue in CB-MSC transplanted wounds (red box with
dotted line) appeared to be thicker and larger than in BM-MSC,
PB-MSC or vehicle medium treated wounds, and it continuously
improved day by day (Fig. 4C).
Re-epithelialization, which was examined using CK 6 Ab
staining, was similar until day three or four (data not shown), after
which re-epithelialization accelerated. At day 8 after treatment,
re-epithelialization occurred rapidly in the CB-MSC transplanta-
tion group compared with the control groups (Fig. 4D). At day 8
after treatment, scar area was the smallest in the CB-MSC
transplanted wound and CK 6-positive epithelial cells covered
Figure 4. Comparison of the therapeutic effect of BM-, CB- and PB-MSCs on wound disease model mouse. (A) Representative
photographs of wounds after treatment with control vehicle medium (medium control), BM-MSC (3610
6 cells), CB-MSC (3610
6 cells) and PB-MSC
(3610
6 cells) by subcutaneous injection around the wound site. (B) Measurement of wound closing at different days. Data (reach group: n=6) are
presented as the mean S.D., and asterisks indicate statistically significant values. The significance of differences was evaluated by Student’s t-test (SAS
version 8.0, Cary, NC, USA). *p,0.05, **p,0.01 (C) CK 6 staining of control medium, BM-MSC (3610
6 cells), CB-MSC (3610
6 cells) and PB-MSC (3610
6
cells) treatment groups on days 8. Red arrows mean CK-6 positive re-epithelilazed region in CB-MSC transplantation group.
doi:10.1371/journal.pone.0032350.g004
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granulation tissue in CB-MSC transplanted wounds, CK 6-
positive re-epithelialized tissue in CB-MSC transplanted wounds
(red arrow region) appeared to be thicker and larger than in BM-
MSC, PB-MSC or vehicle medium treated wounds, and it
continuously improved day by day (Fig. 4D).
However, the BM-MSC, PB-MSC transplantation and vehicle
control medium-treated groups still showed large scars and
incomplete re-epithelialization with the wide wound epithelial
gaps.
Confirmation of anti-oxidant, detoxification and
cytoskeleton molecular expression pattern using western
blot and real-time RT-PCR analysis
Proteins were regarded as strikingly differentially expressed
across BM-MSCs, CB-MSCs, and PB-MSCs in the undifferenti-
ated stage when the magnitude of difference was greater than 2
fold or more. As a result, five proteins were found to have highly
differential expression among MSCs derived from different
sources; they included carbonyl reductase 1 (spot 16), OAT (spot
8), HSP27 (spot 29), GIPC1 (spot 9), PSAT1 (spot 10, 11, 12)
ANXA 1 (spot 17) and GST (spot 30,31) shown as enlarged
protein spots in Fig. 5A. In brief, CBR1 was expressed at a higher
level in BM-MSCs as compared with CB-MSCs and PB-MSCs.
Both OAT and GIPC1 were expressed at a higher level in PB-
MSCs. BM-MSCs and CB-MSC showed a higher expression of
HSP27 as compared with PB-MSCs. PSAT1 was expressed in
BM-MSCs and PB-MSCs. ANXA 1 and GST were higher in CB-
MSC than BM- and PB-MSC (Fig. 5B).
To confirm the results obtained in 2D-DE gels, several proteins,
such as CBR1, OAT, HSP27, GIPC1, PSAT1, ANXA 1 and GST
from three sources of MSCs were selected for further analyses by
using Western blot and real-time RT-PCR analysis.
To quantitatively confirm expression patterns, we performed
Western blot analysis and compared the degree of expression using
an imaging analysis program (Fig. 5C).
Western blot analysis of undifferentiated BM-MSCs, CB-MSCs
and PB-MSCs showed that CBR1 was highly expressed in BM-
MSCs as compared with its expression in CB-MSCs and PB-
MSCs, whereas OAT and GIPC1 were expressed more in PB-
MSCs. PSAT1 was expressed in BM-MSCs and PB-MSCs.
HSP27 was highly expressed in BM-MSCs. ANXA 1 and GST
were higher in CB-MSC than BM- and PB-MSC, as also shown in
the 2-DE results in Fig. 5A and B.
To verify their genomic-level expression, we performed real-
time RT-PCR analysis together with western blot analysis. The
expression pattern of OAT, HSP 27, GIPC 1 and PSAT 1 across
BM-MSCs, CB-MSCs and PB-MSCs were generally comparable
to 2-DE and western blot analysis, except for the results for CBR
1. CBR1 was highly expressed in BM-MSCs as compared with its
expression in CB-MSCs and PB-MSCs. The expression quantity
in CB-MSCs and PB-MSCs was similar in 2-DE and western blot
analysis, whereas in CB-MSCs, it was extremely low as compared
to PB-MSC according to real-time RT-PCR analysis. ANXA 1
and GST were highly expressed in CB-MSC than BM- and PB-
MSC (Fig. 5D).
Immunofluorescent-staining photomicrography for
protein expression patterns and localization
Immunocytochemical staining also verified the expression
patterns and the expression localization of five proteins across
the three different MSCs (Fig. 6).
Although quantitative analysis is not enough when using
immunocytochemical analysis, the examination of expressing
localization is also an important aspect to consider when discussing
functional activity.
CBR1 is an oxidoreductase, which plays a role in oxidation
reduction. It is localized in cytoplasmic portion of widely
distributed tissues in the human body. OAT is an enzyme
involved in visual perception; its expression is normally observed
in mitochondria in the cytoplasm.
HSP 27 is one of the representative proteins involved in stress
resistance and actin organization. HSP 27 is detected in the
cytoplasm of several tissues, including skeletal muscle, heart, aorta,
large intestine, small intestine, stomach, esophagus and many
others. The highest of expression are found in the heart and in
tissues composed of striated and smooth muscle.
GIPC 1 is the actin-binding protein that influences endothelial
cell migration. GIPC 1 is widely expressed in the cytoplasm of
many tissues.
PSAT 1 is expressed in the cytoplasm and nucleus; it is
expressed at high levels in the brain, liver, kidney and pancreas,
whereas it is very weakly expressed in the thymus, prostate, testis
and colon.
According to immunocytochemical analysis in this study, the
localization of CBR 1, OAT, HSP 27, GIPC 1 and PSAT 1 across
the three types of MSCs was similar to that seen in previous
studies. In particular, in CB-MSCs, the localization of PSAT 1 was
more concentrated in the nucleus as compared with the BM-
MSCs and PB-MSCs. In this study, all protein information was
available and searched on NCBI and UniProt KB databases.
Expression pattern of target genes and proteins during
adipogenic and osteogenic differentiation
The relationship between differentiation capacity and the
involvement of specific molecules on differentiation is also
important to consider. Therefore, we examined molecular
expression patterns during differentiation. Additionally, we inves-
tigated the involvement of these target proteins, including CBR 1,
OAT, HSP 27, GIPC 1 and PSAT 1, during MSC differentiation
and verified their protein expression pattern relating to adipogen-
esis and osteogenesis using real-time RT-PCR analysis and
immunocytochemistry.
As compared with undifferentiated MSCs, all proteins were
down-regulated during adipogenic and osteogenic differentiation
in all three different MSCs (data not shown).
Interestingly, when differentiating into adipocytes and osteo-
cytes, the five target proteins showed specific gene expression
patterns, regardless of their cellular source and MSC expression
pattern in an undifferentiated state. The expression of all five
proteins was highest in BM-MSCs, whereas their expression
decreased slightly in CB-MSCs and PB-MSCs. In contrast, the
expression of the five proteins slightly increased in CB-MSCs and
PB-MSCs as compared BM-MSCs (Fig. 7).
To verify their expression localization, we also performed
immunostaining analysis after adipogenic and osteogenic differ-
entiation in the three types of MSCs (Fig. 8). Although the
expression pattern was dissimilar to the undifferentiating stage of
the MSCs, expression localization in the cytoplasm lasted after
adipogenic and osteogenic differentiation in the case of CBR1,
OAT, HSP 27 and GIPC 1. This was the same result as that for
the undifferentiated MSCs. Specifically, in the case of PSAT 1,
expression was more concentrated in the nucleus in CB-MSCs
after differentiation into adipocytes. Additionally, the localization
of PSAT 1 was more robust in the cytoplasm in PB-MSCs after
differentiating into osteocytes as compared to the undifferentiated
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expression levels between the three cell types under investigation
based on their tissue orientation toward adipogenic and osteogenic
differentiation.
Discussion
Since the discovery of MSCs in bone marrow in 1976, MSCs
have been shown to have promise for clinical applications due to
their accessibility, expandability and multipotentiality [5]. How-
ever, the shortage of donor cells and the deeply invasive methods
needed to obtain bone marrow has created a major problem in
transplantation medicine using BM-MSCs. This problem could be
alleviated through the use of other stem cell sources, such as fatty
tissue, placenta, umbilical cord blood, peripheral blood, pancreas,
dental pulp and synovial fluid. Among them, umbilical cord blood
and peripheral blood are considered to be the most suitable stem
cell sources because they are easy to obtain through circulation
with non-invasive method [6,9,13,14,15].
During the past decade, there has been an increase in research
activity aimed at understanding the cellular and molecular aspects
of cell proliferation and differentiation of various sources of stem
cells because the molecular events governing their expansion and
differentiation remain poorly understood.
Therefore, as a first step to understanding the different
molecular expression patterns that govern MSCs function
differently based on cellular source, we proteome-profiled MSCs
to identify differentially expressed key regulatory factors and
discussed their functional role in specific pathological conditions.
Such an analysis may be crucial to eventually determine the most
suitable cell source for a target disease. This information should
thus greatly contribute to the field of cell therapy.
To compare MSCs using proteomic analysis, we derived MSCs
from umbilical cord blood and peripheral blood and characterized
them in comparison to purchased BM-MSCs. In phenotypic
Figure 5. Confirmation of differentially expressed proteins and genes using western blot and real-time RT-PCR analysis. (A) Enlarged
images of differentially expressed protein spots among BM-MSCs, CB-MSCs, and PB-MSCs. (B) The amount of protein expression was measured by
scanning and the TINA analysis program. (C) Confirmation of differentially expressed proteins in MSCs by Western blot analysis (that is, CBR1, OAT,
HSP27, GIPC1, PSAT1, ANXA 1 and GST). Actin was used as an internal control. (D) Real-time RT-PCR analysis of human of CBR1, OAT, HSP27, GIPC1,
PSAT1, ANXA 1 and GST in BM-MSCs, CB-MSCs, and PB-MSC. Data (n=3) are presented as the mean S.D., and asterisks indicate statistically significant
values. The significance of differences was evaluated by independent samples Student’s t-test (SAS version 8.0, Cary, NC, USA). *p,0.05, **p,0.01 and
***p,0.001, compared with BM-MSC.
doi:10.1371/journal.pone.0032350.g005
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MSCs and PB-MSCs) showed similar fibroblastic and spindle-like
morphological appearances. During surface-marker expression
analysis using the FACs analyzer, they were shown to retain
similar marker expression profiles, which were positive for
mesenchymal (CD90) and adhesion markers (CD44) and negative
for hematopoietic markers (CD34, CD45 and CD133). BM-
MSCs, CB-MSCs and PB-MSCs all exhibited general MSC
characteristics in phenotypic analysis in the undifferentiated state,
as has been previously reported. However, when MSCs are
differentiated into three mature cell types (namely, adipocytes,
osteoblasts and chondrocytes), the MSCs showed different
differentiation potentials based on cellular source during an
analysis to confirm their multipotent ability. Our data indicated
that BM-MSCs have a higher potential to undergo adipogenesis,
osteogenesis and chondrogenesis than other MSCs. Although
MSCs from three different sources were highly similar in the
undifferentiated state, these differences in differentiation capacity
could be functionally related to the MSC source.
Next, proteomic approaches were applied in order to identify
the respective regulatory molecules. The protein expression
profiles among BM-MSCs, CB-MSCs and PB-MSCs were
compared using 2-DE and combined MS/MS analysis.
Despite the similar general protein expression patterns of the
three MSC types, 11 of the proteins were abundantly up-regulated
in BM-MSCs and CB-MSCs, and 16 of the proteins were up-
regulated in PB-MSCs.
Identified proteins that specifically up-regulated in BM-MSCs,
CB-MSCs and PB-MSCs were classified according to their
biological processes and molecular functions based on gene
ontology. They were also grouped into different categories
according to their functions as documented on the Gene Ontology
and UniProt websites, including cytoskeleton proteins, antioxidant
and detoxification proteins, viral defense-related proteins, enzymes
and development-related protein. The protein expression profile is
specifically expressed in one cell type or overlapped across the
three MSC types. Cytoskeletal proteins were abundantly expressed
in PB-MSCs (that is, tubulin alpha 1 C chain, annexin A2, lamin
B1, PDZ domain-containing protein GIPC 1 and actin), and some
of these proteins were also strongly expressed in BM-MSCs
(namely, tubulin alpha 1 C chain and annexin A2). Furthermore,
antioxidant and detoxification proteins were abundantly expressed
in both BM-MSCs (namely, carbonyl reductase [NADPH], heat
shock proteins beta 1 (HSP 27), glutathione S-transferase Mu3 and
glutathione S-transferase omega-1) and CB-MSCs (namely, heat
shock proteins beta 1 (HSP 27), glutathione S-transferase Mu3,
glutathione S-transferase omega-1, S-formylglutathione hydrolase,
anexxin A1 and chloride intracellular channel protein 4).
These expression profiles may be correlated with functional
behavior in vivo because cytoskeleton and anti-oxidant and
detoxification roles are considered to be the most important
aspect of cell engraftment and survival in ischemic or damaged
tissue regions [24,25]. Indeed, these are the regions in which cell
transplantation of MSCs are performed to cure degenerative
diseases, such as cardiovascular or neurodegenerative disease
[2,3]. Cytoskeleton proteins participate in the improvement of cell
migration and engraftment, and antioxidant and detoxification
proteins enhance cell survival ability under harsh conditions, such
as during hypoxia, in the ischemic region [26,27,28]. In such
conditions, when the protein expression profile corresponds to in
vivo functional performance, PB-MSCs will be retain remarkable
engraftment and/or migration abilities due to their up-regulated
cytoskeleton protein expression. In addition, the high migration
ability of PB-MSCs could be a natural result because PB-MSCs
are mobilized cell population from bone marrow. Also, CB-MSCs
and PB-MSCs could be a more optimal cellular source for vascular
or neural degenerative disease caused by hypoxic conditions in the
ischemic region of damaged tissue due to their highly up-regulated
proteins, which are involved in antioxidant and detoxification
function. Moreover, co-transplantation of different MSCs could
exhibit both high engraftment and migration ability and antiox-
idant and detoxification function.
To investigate these points which related to functional relevance
between specifically up-regulated molecules and each cell lines
including BM-, CB- and PB-MSC, we generated wound disease
model and compared their therapeutic capacity in ischemic tissue
when cells transplanted. It is possible that comparison of functional
behavior of each cells in ischemic tissue on wound healing disease
model, because wound is one of the most frequently developed
disease associated with several kinds of ischemic disease model.
In comparison, CB-MSC transplanted group was shown the
highest therapeutic ability at the point of re-formation of
granulation tissue and re-epithelialization on wound site.
Therapeutic effect after stem cell therapy is really closed with
cell survival rate and cell engraftment efficacy on the damaged site.
Figure 6. Immunofluorescent-staining photomicrography for
protein expressed in undifferentiated BM-MSCs, CB-MSCs, and
PB-MSCs. Blue color is DAPI staining. Scale bar: 20 mm.
doi:10.1371/journal.pone.0032350.g006
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difficult due to the technical limitation and the very extremely low
cell engraftment efficacy, because it is well known that cell
engraftment efficacy of stem cell therapy is less than 1%. This
means that cell survival capacity is one kind of important aspect of
healing process.
In this study, anti-oxidant, detoxification and anti-apoptosis
related molecules, including heat shock proteins beta 1 (HSP 27),
glutathione S-transferase Mu3, glutathione S-transferase omega-1,
S-formylglutathione hydrolase, anexxin A1 and chloride intracel-
lular channel protein 4, were specifically up-regulated and the
therapeutic effect was the highest in CB-MSC than BM-MSC or
PB-MSC.
These result suggest that CB-MSCs could be a more optimal
cellular source for ischemic disease caused by hypoxic conditions
due to their highly up-regulated proteins, which are involved in
antioxidant and detoxification function, and these function have
more dominant position in therapeutic capacity than cytoskeleton
function, when the protein expression profile corresponds to in
vivo functional performance.
Another analytical approach of this study required the use of
proteomics to identify the product of cell fate regulation and
differentiation of MSCs based on their cellular source.
Before starting this study, we hypothesized that MSCs obtained
from different cellular sources would exhibit different differenti-
ation potential according to their source because cell microenvi-
ronments are one of the most important factors for differentiation.
In our in vitro differentiation study, BM-MSCs were most likely to
result in adipogenic, osteogenic and chondrogenic differentiation.
To elucidate functional regulator that govern the differing
differentiation potential of MSCs, we selected five extremely
differentially expressed proteins (namely, CBR1, OAT, HSP27,
GIPC1, and PSAT1) and verified their expression pattern in
undifferentiated and differentiated states using western blotting
and real-time RT-PCR. In the undifferentiating state, CBR 1 was
extremely up-regulated in BM-MSCs, whereas OAT and GIPC
were dramatically up-regulated in PB-MSCs. Additionally, HSP
27 was up-regulated in BM-MSCs and CB-MSCs, and PSAT was
up-regulated in BM-MSCs and PB-MSCs. Interestingly, when
MSCs differentiated into adipogenic cells, these proteins were all
highly expressed in BM-MSC-derived adipocytes as compared to
CB-MSC-derived adipocytes. PB-MSC-derived adipocytes
showed the lowest expression of all five proteins. However, these
proteins were all highly expressed in PB-MSC-derived osteocytes
when inducing osteocyte differentiation as compared to CB-MSC-
derived osteocytes. BM-MSC-derived osteocytes showed the
lowest expression of all five proteins. In other words, the
expression profiles were consistently reversed when inducing
adipogenic or osteogenic differentiation, despite being irregular in
the undifferentiated state. This means that the proteins involved in
the differentiation mechanism function in a different manner
according to their cellular source and final destination.
Although functions with respect to oxidoreductase, visual
perception, stress resistance, actin-binding or biosynthesis have
previously been defined, but these functions have not been
described in MSCs, particularly with regard to their roles in MSC
biology [26,27,28,29,30]. Recent data have demonstrated for the
first time the implication of CBR1, OAT, HSP27, GIPC1 and
PSAT1 in the differentiation of MSCs to both adipogenic and
osteogenic lineages.
These results should provide a new direction for research
focused on the development of potential therapeutic pathways
using proteomics.
Figure 7. Expression pattern of target genes during adipogenic and osteogenic differentiation using real-time RT-PCR analysis.
Data (n=3) are presented as the mean S.D., and asterisks indicate statistically significant values. The significance of differences was evaluated by
paired independent samples Student’s t-test (SAS version 8.0, Cary, NC, USA). NC=no significant differences, *p,0.05,* * p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0032350.g007
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we showed that the differentiation rate was highest in BM-MSCs
in both adipogenic and osteogenic differentiation; the relationship
between differentiation rates and expression patterns of CBR1,
OAT, HSP27, GIPC1 and PSAT1 may suggest another interpre-
tation. When BM-MSCs were differentiated into adipocytes or
osteocytes, the expressions of CBR1, OAT, HSP27, GIPC1 and
PSAT1 were the highest and lowest in BM-MSC-derived
differentiated adipocytes and osteocytes, respectively. This could
mean that CBR1, OAT, HSP27, GIPC1 and PSAT1 up-regulate
adipogenic differentiation and down-regulate osteogenic differen-
tiation in BM-MSCs. In addition, if CBR1, OAT, HSP27, GIPC1
and PSAT1 were manipulated artificially in vitro in other cell
types of MSC, one might be able to regulate differentiation into
adipocytes or osteocytes, much like BM-MSCs.
During immuno-staining analysis used to verify the expression
localization, it was discovered that PSAT 1 is normally expressed
in the cytoplasm and nucleus. In this study, the expression of
PSAT was more concentrated in the nucleus of CB-MSCs as
compared to BM-MSCs or PB-MSCs. In other words, cellular
localization was more directed toward the cytoplasm in PB-MSCs
after differentiating into osteocytes as compared to that in the
undifferentiated state. These localization changes in specific
proteins could also be a valuable clue for regulating differentiation
into specific cell lineages.
Finally, there is a need for more additional studies investigating
about the mechanisms which affect to healing process and these
key regulatory factors during differentiation. The findings of the
present study suggested that the different in vivo functions of
MSCs may depend on their specific protein expression profile and
their expressed location, and their differentiation potential could
control key regulatory factors, such as CBR1, OAT, HSP27,
GIPC1 and PSAT1, in different manners according to their
cellular source and final destination.
In conclusion, we have demonstrated significant differences in
the properties of MSCs depending on their cell source beyond
donor and experimental variation. These results provide impor-
tant information for selecting the optimal mesenchymal tissue as a
source of cells and for enhancing clinical utility. For instance, CB-
Figure 8. Immunofluorescent-staining photomicrography for protein expressed in differentiated adipocytes and osteoblasts. Blue
color is DAPI staining. Scale bar: 20 mm.
doi:10.1371/journal.pone.0032350.g008
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increasing revascularization than PB-MSCs.
In this report, we presented for the first time large datasets of
proteins involved in the mechanisms and pathways that regulate
stem cell differentiation using a proteomic approach. The insights
obtained in stem cell biology should provide many opportunities to
improve public health. That is, this study of stem cell biology using
proteomic analysis should contribute greatly to gaining insight into
stem cell functioning and behavior. The results should provide
clues for how to improve the cellular effect of transplantation in
the field of regenerative medicine.
Materials and Methods
Isolation and culture of human MSCs from cord blood,
peripheral blood and bone marrow
Human umbilical cord blood and peripheral blood samples
were collected in NH Sodium Heparin–coated tubes (Greiner Bio-
One, Kremsmunster, Austria) from healthy volunteers. BM-MSCs
were purchased from Cambrex (Lonza Walkersville, Inc, MD,
U.S.A.). Blood was diluted 1:3 with D-PBS (Invitrogen, Carlsbad,
CA) and overlaid onto Ficoll-Paque (Amersham, Piscataway, NJ).
Cells were centrifuged at 2500 rpm for 30 minutes. Buffy coat
mononuclear cells (MNCs) were collected and washed three times
in D-PBS. MNCs were resuspended in MEM alpha medium
(Gibco, New York, NY, U.S.A.) supplemented with glutamax
(Gibco), penicillin (Gibco), streptomycin (Gibco), and 10% fetal
bovine serum (Gibco). Cells were seeded on 10 cm culture dishes
(Nunc, Roskilde, Denmark). After 4 days of culture, nonadherent
cells and debris were aspirated, and MEM alpha medium was
added. The medium was changed after 6 days. We used general
cell passaging procedure using trypsinization and passage 3–5 of
BM-, CB- and PB-MSCs were used in all these experiments.
In derivation, the initial seeding MNC number was 4.2856106
cells / T-75 flask in average.
RT-PCR and quantitative real-time RT-PCR analysis
Total RNA was isolated using the Trizol reagent (Invitrogen).
RNA (1 mg) was reverse-transcribed into cDNA using maxime RT
premix (Intron) according to the manufacturer’s instruction. In
brief, the reverse transcription reaction was carried out in a 20 ul
mixture at 45uC for 60 minutes. Standard PCR conditions
included 2 minutes at 95uC, followed by 22–28 cycles of 30
seconds of denaturing at 95uC, then 30 seconds of annealing at
55uC and 1 minute of extension at 72uC. Primer sequences are
listed in Table S1.
For real-time RT-PCR analysis, total RNA and cDNA were
prepared with the same method as in the RT-PCR analysis. Real-
time quantitative RT-PCR primers were targeted to adipogenic
marker PPARc2, osteogenic marker ALP (alkaline phosphatase),
CRB1, GIPC1, OAT, PSAT1 and HSP27. Primer sequences are
listed in Table S2.
Quantification was performed using SyBr Green gene expres-
sion assays (Roche, Mannheim, Germany). The level of target
gene expression was determined by the comparative Ct method,
whereby the target is normalized to the endogenous reference b-
actin. The Ct value is the cycle number at which the fluorescence
level reaches a given threshold. DCt is determined by subtracting
the Ct value of the b-actin control from the Ct value of target gene
[DCt = Ct (target) –Ct (b-actin)]. This relative value of target to
endogenous reference is described as the fold of b-actin =2
2DCt.
2-dimensional electrophoresis (2-DE) analysis and protein
identification
CB-MSCs, PB-MSCs and BM-MSCs were prepared for protein
extraction at passage 5 and cultured in MEM alpha medium
(Gibco, New York, NY, U.S.A.) supplemented with glutamax
(Gibco), penicillin (Gibco), streptomycin (Gibco), and 10% fetal
bovine serum (Gibco). Pro-Prep Protein Extraction Solution
(iNtRON Biotechnology) was added to each sample, and total
quantity of protein (300 mg) for the analytical runs was transferred
into IPG strip holder channels (Bio-Rad). 2-DE protein mixtures
were separated by IEF in the first dimension and SDS-PAGE in
the second dimension. Total proteins were mixed with rehydration
solution (7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 50 M DTT
and a trace of bromophenol blue) for a final volume of 300 ml and
the incubated for 12 h at RT before separation by IEF at 250 V
for 15 min, 1,000 V for 2 h, or 1,000 V for 6 h, with 50 mA per
gel strip. The gel strips were then immediately equilibrated in
equilibrium buffer (50 mM Tris-HCl, pH 8.8, 6 M urea, 30% (v/
v) glycerol, and 2% (w/v) SDS). After equilibration, the IPG gel
strips were transferred for the second dimension onto SDS-PAGE
followed by electrophoresis in a Protean II xi 2-DE cell (Bio-Rad)
at 20 mA.
The 2-DE gels were stained using a Silver Staining Kit. Briefly,
the gels were fixed in 40% ethanol and 10% acetic acid for 30 min
and then sensitized in a solution of 25% (w/v) ethanol
glutaraldehyde, 5% (w/v) sodium thiosulfate and 17 g of sodium
acetate for 30 min. Finally, they were washed three times with
water for 15 min each time. The gels were subsequently immersed
in 2.5% (w/v) silver nitrate and 37% (w/v) formaldehyde for
20 min and then developed in a mixture of 6.25 g of sodium
carbonate and 37% (w/v) formaldehyde for 2–5 min. The
reaction was then stopped in EDTA-Na2-2H2O.
The silver-stained gels were scanned with an ImageScanner
(Amersham, USA) and analyzed with Phoretix Expression
software (ver. 2005; Nonlinear Dynamics, UK). Destaining and
in-gel tryptic digestion of the protein spots were performed as
described [31].
Ethics
Human umbilical cord blood and peripheral blood samples
were donated from healthy volunteers in CHA general hospital.
The research was approved by the Korean Ministry of Health and
Welfare (national approval number 86) under the Bioethics Law.
On the basis of this national approval, our work was re-approved
for the use of cord blood and peripheral blood by the IRB of CHA
University.
Animals and wound model
All animal procedures were approved under the guidelines of
the Health Sciences Animal Policy and Welfare Committee of the
CHA University College of Medicine.
Balb/C nude mice (6–8 weeks old, male, bodyweight 25–30 g)
were anesthetized with an intraperitoneal injection of 100 ml of a
solution containing 2.22 mg ketamine and 0.17 mg xylazine. After
disinfecting the dorsal surface of each mouse with an alcohol swab,
two 6-mm full-thickness excisional skin wounds were created on
both sides of the dorsal surface using a 6-mm biopsy punch device.
Each wound received 3610
6 cells/ml of BM-, CB- and PB-MSCs
or control vehicle medium through subcutaneous injection around
the wound.
Each group underwent experiments to evaluate all wounds at
seven time points for14 days post-surgery (n=6 at each time point
for each group).
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Digital photographs of the wounds were taken for 14 days. The
time to wound closure was defined as the time at which the wound
bed was completely re-epithelialized and filled with new tissue.
The wound area was measured by tracing the wound margin
including the scar area and was calculated using an image analysis
program (Image J). The investigators who measured the samples
were blinded to the group and treatment. The percentage of
wound closure was calculated as (area of original wound – area of
actual wound)/area of original wound 6100. The mice were
sacrificed and skin and tissue were harvested from the wound area.
Immunohistochemical analysis
Tissue specimens were fixed in 10% freshly prepared parafor-
maldehyde for seven days, dehydrated with a graded ethanol
series, embedded in paraffin, and cut into 6-mm-thick sections.
These sections were deparaffinized, hydrated and stained for CK-
6, CD 3 and PECAM. Staining was performed using a standard
method, and all reagents were purchased from Sigma-Aldrich.
Tissue sections were analyzed using light microscopy (Nikon).
Statistical analysis
The quantitative data are expressed as the mean 6 SD. The
statistical analysis was performed using the t-test. A value of
P,0.05 was considered statistically significant.
Other material and method were available in Material and
Method S1.
Supporting Information
Figure S1 Morphological change during cell derivation
of CB-MSCs and PB-MSCs. BM-MSCs were purchased from
Cambrex to use as a representative control for MSCs. Immedi-
ately after isolation of CB-MSCs and PB-MSCs using Ficoll
reagent, at day 1, only a few single cells attached to the culture
dish did not form any adherent colonies. After 14 days, adherent
colony forming cells appeared (passage 0), and proliferating MSCs
exhibited fibroblastic and spindle-like morphology after passage 2.
This was the same as purchased BM-MSCs.
(TIF)
Figure S2 Cell growth curves of BM-, CB- and PB-MSCs.
Cell growth was recorded by ECICs (Electric Cell-substrate
Impedance Sensing, Applied BioPhysics) for 40 hrs. A: BM-MSC,
B:CB-MSC, C:PB-MSC, D: BM-MSC, E:CB-MSC, F:PB-MSC.
(TIF)
Material and Method S1
(DOC)
Table S1 Primers pairs used in RT-PCR analysis.
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Table S2 Primers pairs used in Real-time RT-PCR
analysis.
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Table S3 Up-regulated molecules in BM-MSCs.
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Table S4 Up-regulated molecules in CB-MSCs.
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Table S5 Up-regulated molecules in PB-MSCs.
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